# OnCo record secondary-malignancy (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/secondary-malignancy/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "secondary-malignancy" ;
  schema:name "Secondary malignancy (therapy-related cancer)"@en ;
  schema:alternateName "secondary malignancies"@en, "second malignancy"@en, "second malignancies"@en, "second cancer"@en, "second cancers"@en, "second primary"@en, "second primary cancer"@en, "second primary cancers"@en, "second primary malignancy"@en, "therapy-related"@en, "treatment-related cancer"@en, "treatment-induced cancer"@en, "therapy-related AML"@en, "therapy-related MDS"@en, "therapy-related myeloid neoplasm"@en, "t-MN"@en, "t-AML"@en, "radiation-induced"@en, "radiation-induced cancer"@en, "radiation-induced sarcoma"@en, "secondary leukaemia"@en, "secondary leukemia"@en, "secondary AML"@en, "T-cell lymphoma after CAR-T"@en, "T-cell malignancies"@en, "second primaries"@en, "second primary malignancies"@en, "T-cell malignancy"@en, "therapy-related myeloid neoplasms"@en ;
  schema:description "A new, different cancer caused by the treatment of the first one: leukaemia after alkylating chemotherapy or PARP inhibitors, solid tumours in irradiated tissue decades later, and rarely T-cell lymphoma after CAR-T. Rare per patient, but it matters most for those cured young."@en ;
  schema:url <https://onco.cc/terms/secondary-malignancy/> ;
  schema:dateModified "2026-09-09"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Secondary_malignant_neoplasm> ;
  schema:citation <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/secondary-cancer>, <https://doi.org/10.1056/NEJMoa1505949>, <https://www.gov.uk/government/publications/breast-screening-higher-risk-women-surveillance-protocols/protocols-for-surveillance-of-women-at-higher-risk-of-developing-breast-cancer>, <https://lymphoma-action.org.uk/news/annual-breast-screening-missed-following-radiotherapy-hodgkin-lymphoma> ;
  onco:related <https://onco.cc/cancers/mds/>, <https://onco.cc/pathways/clonal-haematopoiesis/>, <https://onco.cc/terms/late-effects/>, <https://onco.cc/terms/alkylating-agent/>, <https://onco.cc/terms/anthracycline/> ;
  onco:cancers <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/early-stage-classical-hodgkin-lymphoma/>, <https://onco.cc/cancers/advanced-stage-classical-hodgkin-lymphoma/>, <https://onco.cc/cancers/relapsed-refractory-hodgkin-lymphoma/>, <https://onco.cc/cancers/nodular-lymphocyte-predominant-hodgkin-lymphoma/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/>, <https://onco.cc/cancers/dlbcl/> ;
  onco:sections <https://onco.cc/fronts/supportive-care/> .